GSK vs REGN: stock comparison and AI forecast
Gsk Plc (GSK) and Regeneron Pharmaceuticals, Inc. (REGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GSK Gsk Plc
- Market Cap
- $98.25B
- P/E Ratio
- 5.4x
- Size
- large-cap
- AI Forecast
REGN Regeneron Pharmaceuticals, Inc.
- Market Cap
- $98.97B
- P/E Ratio
- 21.3x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- GSK and REGN have similar market capitalizations ($98.25B and $98.97B).
- GSK trades at 5.4 times trailing earnings, REGN at 21.3 times.
- GSK carries 2.76 times debt per unit of equity, against 0.33 times for REGN.
- REGN yields 0.39% in dividends; GSK pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GSK | REGN |
|---|---|---|
| Market Cap | $98.25B | $98.97B |
| P/E Ratio | 5.37x | 21.28x |
| P/B Ratio | – | 2.95x |
| Dividend Yield | – | 0.39% |
| EPS | $9.08 | $45.18 |
| Book Value/Share | – | $325.37 |
| Revenue/Share | $81.00 | $164.11 |
| FCF/Share | $15.23 | $37.16 |
Profitability & Margins
| Metric | GSK | REGN |
|---|---|---|
| ROE | – | 18.4% |
| ROA | – | 13.9% |
| ROIC | – | 12.7% |
| Gross Margin | 70.8% | – |
| Operating Margin | 20.3% | 28.8% |
| Net Margin | – | 36.5% |
| EBT Margin | 18.2% | 33.6% |
| Tax Rate | 13.7% | 15.3% |
Financial Health
| Metric | GSK | REGN |
|---|---|---|
| Current Ratio | 0.82x | 3.35x |
| Quick Ratio | 0.54x | 2.89x |
| D/E Ratio | 2.76x | 0.33x |
| Financial Leverage | – | 1.33x |
| Interest Coverage | – | 21.1x |
| Working Capital | -$5.23B | $14.59B |
Cash Flow
| Metric | GSK | REGN |
|---|---|---|
| Operating Cash Flow | $37.61B | $4.85B |
| Free Cash Flow | $30.73B | $3.83B |
| Capital Spending | -$6.88B | -$1.02B |
| OCF Growth YoY | -13.3% | -4.4% |
| FCF Growth YoY | 0.0% | -9.4% |
| FCF/Sales | 18.8% | 22.6% |
| CapEx/Sales | 4.2% | 6.0% |
Operational Efficiency
| Metric | GSK | REGN |
|---|---|---|
| Asset Turnover | – | 0.38x |
| Receivables Turnover | 16.6x | 2.2x |
| Inventory Turnover | 6.1x | – |
| Fixed Assets Turnover | 13.3x | 3.0x |
| Days Sales Outstanding | 22 days | 164 days |
| Days Inventory | 60 days | – |
| Payables Period | 155 days | – |
| Cash Conversion Cycle | -73 days | – |
Income Statement
| Metric | GSK | REGN |
|---|---|---|
| Total Revenue | $163.43B | $16.90B |
| Operating Income | $33.20B | $4.86B |
| Net Income | – | $6.17B |
| R&D Expense | $33.87B | $6.60B |
| SG&A Expense | $50.02B | $2.76B |
| Cost of Goods Sold | $47.81B | – |
Dividend & Shareholder Information
| Metric | GSK | REGN |
|---|---|---|
| Dividends Per Share | – | $3.72 |
| Payout Ratio | – | 8.2% |
| Shares Outstanding | 2017M | 103M |
| Net Income Growth | – | 220.3% |
| EPS Growth | 87.6% | 8.0% |
GSK vs REGN: stock comparison and AI forecast
Which is bigger, GSK or REGN?
GSK and REGN have similar market capitalizations ($98.25B and $98.97B).
Which is cheaper on earnings, GSK or REGN?
GSK trades at 5.4 times trailing earnings, REGN at 21.3 times.
Which one does Intratio's AI model rank higher, GSK or REGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.